Life Sciences Tools and Services

Evotec SE

Evotec SE released FY2026 Q1 earnings on May 6 During-Market (EST), actual revenue USD 179.51 M (forecast USD 186.45 M), actual EPS USD -0.3934 (forecast USD -0.2005)

Evotec SE to Release FY2026 Q1 Earnings on May 6 During-Market EST, Forecast Revenue USD 198.76 M, EPS USD -0.2063

RBC Capital Maintains Buy Rating on Evotec

Evotec SE released FY2025 Q4 earnings on April 8 During-Market (EST), actual revenue USD 297.48 M (forecast USD 311.91 M), actual EPS USD 0.0483 (forecast USD 0.0822)

Evotec SE released FY2025 earnings on April 8 During-Market EST, actual revenue USD 0 (forecast USD 937.39 M), actual EPS USD 0 (forecast USD -0.7321)

Evotec SE to Release FY2025 Q4 Earnings on April 8 During-Market EST, Forecast Revenue USD 305.1 M, EPS USD 0.0804

Goldman Sachs Significantly Reduces Stake in Evotec SE

JPMorgan Reduced Its Voting Rights in Evotec SE

JPMorgan Increases Voting Rights in Evotec SE

Evotec Receives $5 Million Milestone Payment from BMS and IND Application Accepted by FDA

Evotec SE released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 192.2 M (forecast USD 224.77 M), actual EPS USD -0.1422 (forecast USD -0.1954)

Evotec SE released FY2025 9 Months Earnings on November 5, 2025 (EST), with actual revenue of USD 609.11 M and EPS of USD -0.3817

Weston Analyzes and Recommends Healthcare Industry Stocks

Evotec SE Signs Acquisition and Technology Licensing Agreement with Sandoz AG

Evotec SE to Release FY2025 Q3 Earnings on November 4, 2025 (EST), Forecast Revenue USD 223.07 M, EPS USD -0.1939

Evotec SE released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 200.44 M (forecast USD 236.47 M), actual EPS USD -0.1433 (forecast USD -0.1521)

Evotec SE released FY2025 Semi-Annual Earnings on August 13 (EST), with actual revenue of USD 418.18 M and EPS of USD -0.238

Evotec SE to Release FY2025 Semi-Annual Earnings on August 12, 2025 (EST)

Sandoz Plans to Acquire Just-Evotec Biologics for $300 Million

Evotec SE Joins NURTuRE-AKI Consortium for AKI Drug Discovery

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

Evotec SE announced the results of its 2026 Annual General Meeting, where all agenda items were adopted. Dieter Weinand and Dr. Wolfgang Hofmann were newly elected to the Supervisory Board, with Weinand appointed as Chairman. Dr. Duncan McHale and Wesley Wheeler were re-elected. Shareholder representation stood at 43.10% of registered capital.

StockTitan

Evotec Reports Results of the Annual General Meeting 2026 | EVO Stock News

Evotec Appoints Rui Wang as Head of Global In Silico and AI | EVO Stock News

Evotec Appoints Rui Wang as Head of Global In Silico and AI | EVO Stock News

SBIO

IBBQ

LABU

Evotec SE Successfully Placed €116.1 Million Convertible Bonds | EVO Stock News

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Evotec SE Successfully Placed €116.1 Million Convertible Bonds | EVO Stock News

TD Cowen analyst Brendan Smith has maintained a Buy rating on Evotec AG (EVO) with a price target of $4.00, while the stock closed at $3.24. The analyst has an average return of 3.2% and a 38.76% success rate. Evotec AG has a consensus rating of Moderate Buy, with a price target consensus of $4.67, indicating a potential upside of 44.14%. H.C. Wainwright also reiterated a Buy rating with a $7.00 price target in a previous report.

Tip Ranks

Toronto Dominion Bank

Schrodinger

908 Devices

Alpha Teknova

TD Cowen Remains a Buy on Evotec AG (EVO)

Evotec SE reported a 22% year-on-year revenue decline in Q1 2026, totaling €156.6 million, with an adjusted EBITDA loss of €21.9 million. Despite this, the company confirmed its full-year guidance and aims for over €1 billion in revenues by 2030. Evotec is undergoing a 'Horizon' transformation, streamlining operations and targeting €75 million in savings by 2027. The company appointed new leadership and expects $100 million from its Tubulis stake. Analysts rate EVO stock as a Buy with a $7.00 target, though concerns about financial performance persist.

SANDOZ GROUP AG SPON ADS EACH REP 1 COM SHS

Bristol Myers Squibb

Gilead Sciences

Bristol-Myers Squibb Company

Evotec SE Posts Weak Q1 2026 but Doubles Down on ‘Horizon’ Transformation and Mid-Term Growth Targets

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall | EVO Stock News

iShares Global Healthcare

Health Care Select Sector SPDR

VG Health

Ark Genomic Revolution ETF

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall | EVO Stock News

Evotec AG has announced the nomination of Dr. Wolfgang Hofmann to its Supervisory Board, with a vote scheduled for June 11, 2026. The company aims to strengthen governance by expanding the board from six to seven members and has entered a cooperation agreement with major shareholder MAK Capital Fund LP. This agreement emphasizes active shareholder engagement to enhance long-term value and governance stability. Despite a recent analyst rating of 'Buy' for EVO stock, concerns about financial performance and technical indicators persist, leading to a neutral outlook from analysts.

Evotec Strengthens Supervisory Board and Strikes Governance Pact With MAK Capital

Evotec SE(EVO.US)

Evotec Reports Results of the Annual General Meeting 2026 | EVO Stock News

Evotec Appoints Rui Wang as Head of Global In Silico and AI | EVO Stock News

Evotec SE Successfully Placed €116.1 Million Convertible Bonds | EVO Stock News

TD Cowen Remains a Buy on Evotec AG (EVO)

Evotec SE Posts Weak Q1 2026 but Doubles Down on ‘Horizon’ Transformation and Mid-Term Growth Targets

Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall | EVO Stock News

Evotec Strengthens Supervisory Board and Strikes Governance Pact With MAK Capital